Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion

Journal of Veterinary Pharmacology and Therapeutics

Volumn 29, Issue 2, 2006, Pages 147-152

  Freise, K J ^a,b   Martin Jimenez T ^a,c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; DRUG METABOLITE; GEMCITABINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; DEOXYCYTIDINE; DOGS; FEMALE; FLOXURIDINE; HALF-LIFE; INFUSIONS, INTRAVENOUS; TISSUE DISTRIBUTION;

ANIMALIA; CANIS FAMILIARIS;

EID: 33644681751     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2006.00726.x     Document Type: Article

References (21)

1. Abbruzzese J.L. Grunewald R. Weeks E.A. et al. 1991 A phase I clinical, plasma, and cellular pharmacology study of gemcitabine Journal of Clinical Oncology 9 491 498
2. Cozzi P.J. Bajorin D.F. Tong W. Nguyen H. Scott J. Heston W.D.W. Dalbagni G. 1999 Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs Clinical Cancer Research 5 2629 2637
3. Esumi Y. Mitsugi K. Takao A. Seki H. Kawai H. 1994 Disposition of gemcitabine in rat and dog after single and multiple dosings Xenobiotica 24 805 817
4. Fogli S. Danesi R. De Braud F. De Pas T. Curigliano G. Giovannetti E. Del Tacca M. 2001 Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer Annals of Oncology 12 1553 1559
5. Freeman K.B. Anliker S. Hamilton M. Osborne D. Dhahir P. Nelson R. Allerheiligen S.R.B. 1995 Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection Journal of Chromatography B 665 171 181
6. Freise K. Martín-Jiménez T. 2006 Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics Journal of Veterinary Pharmacology and Therapeutics 29 137 145
7. Grunewald R. Kantarjian H. Keating M.J. Abbruzzese J. Tarasoff P. Plunkett W. 1990 Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia Cancer Research 50 6823 6826
8. Grunewald R. Abbruzzese J.L. Tarassoff P. Plunkett W. 1991 Saturation of 2′2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine Cancer Chemotherapy and Pharmacology 27 258 262
9. Grunewald R. Kantarjian H. Du M. Faucher K. Tarassoff P. Plunkett W. 1992 Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study Journal of Clinical Oncology 10 406 413
10. Huang P. 1995 Fludarabine- and gemcitabine-induced apoptosis: incorportation of analogs into DNA is a critical event Cancer Chemotherapy and Pharmacology 36 181 188
11. Huang P. Chubb S. Hertel L.W. Grindney G.B. Plunkett W. 1991 Action of 2′,2′-difluorodeoxycytidine on DNA synthesis Cancer Research 51 6110 6117
12. Kawai M. Esumi Y. Ishizaki M. Gunji S. Seki H. 1995 Metabolism of gemcitabine in rat and dog Xenobiotica 25 405 416
13. Kuehl R.O. 2000 Design of Experiments: Statistical Principle of Research Design and Analysis 2nd edn Brooks/Cole Publishing Co.
14. Lichtman S.M. Villani G. 2000 Chemotherapy in the elderly: pharmacologic considerations Cancer Control 7 548 556
15. Moore A.S. Kitchell B.E. 2003 New chemotherapy agents in veterinary medicine Veterinary Clinics of North America Small Animal Practice 33 629 649
16. Nabhan C. Krett N. Gandhi V. Rosen S. 2001 Gemcitabine in hematologic malignancies Current Opinion in Oncology 13 514 521
17. Patel S.R. Gandhi V. Jenkins J. Papadopolous N. Burgess M.A. Plager C. Plunkett W. Benjamin R.S. 2001 Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation Journal of Clinical Oncology 19 3483 3489
18. Plunkett W. 1995 Gemcitabine: metabolism, mechanisms of action, and self-potentiation Seminars in Oncology 22 3 10
19. Shipley L.A. Brown T.J. Cornpropst J.D. Hamilton M. Daniels W.D. Culp H.W. 1992 Metabolism and diposition of gemcitabine, an oncolytic deoxycytidine analog, in mice, rats, and dogs Drug Metabolism and Disposition 20 849 855
20. Storniolo A.M. Allerheiligen S.R.B. Pearce H.L. 1997 Preclinical, pharmacologic, and phase I studies of gemcitabine Seminars in Oncology 24 S7-2 S7-7
21. Veerman G. van Haperen V.W.T.R. Vermorken J.B. Noordhuis P. Braakhuis B.J.M. Pinedo H.M. Peters G.J. 1996 Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors Cancer Chemotherapy and Pharmacology 38 335 342